• Call(WhatsApp Us)

    +8615360806100
  • Email Us

    cherry@laeyo.com
  • 广州市花都区花山镇华辉路18号

    微观化妆品创意产业园E栋整栋

How to Transfer a Custom Face Serum to a New Factory Without Losing Gulf Climate Test History

A custom face serum rarely fails a factory transfer because the formula was written down wrong. It fails because the evidence that made the formula sellable — high-temperature storage data, thermal cycling, preservative efficacy,…

Category: Skincare Sourcing Guides • Author: laeyo • Published: 2026-11-02 • Views: 66

A custom face serum rarely fails a factory transfer because the formula was written down wrong. It fails because the evidence that made the formula sellable — high-temperature storage data, thermal cycling, preservative efficacy, packaging compatibility — was tied to a specific formula, preservative system, fragrance, pack and test method, and none of that travels with a spreadsheet of percentages. In Gulf markets, where a serum can spend an August afternoon in a 50 °C delivery van before it reaches a Dubai or Riyadh shelf, that history is effectively the product’s licence to sell. This is a procurement playbook for moving production to a new factory without quietly invalidating it.

What “Gulf climate history” actually consists of

Before you can protect your test history, you need to know exactly which documents you are protecting. For a face serum sold in the GCC, the defensible file usually contains six things — and each one is only valid for the versions of the product it was generated on.

  • Stability data at hot/humid conditions. Long-term storage at Zone IVb conditions (typically 30 °C / 75% RH) plus accelerated data at 40 °C / 75% RH, with defined timepoints (0, 3, 6, 12, 18, 24, 36 months) and test items: appearance, colour, odour, pH, viscosity, active assay where relevant, and micro. Evidence: signed stability report naming the protocol version, storage condition, timepoints, and the batch tested.
  • Thermal cycling / freeze–thaw. Simulates the container actually being loaded, trucked and warehoused. Evidence: cycling report with temperature range, number of cycles, and post-cycle results.
  • Photostability. Critical for vitamin C, retinol and pigment-containing serums in a high-UV market. Evidence: light-exposure test report with packaging condition (primary pack vs. secondary carton).
  • Preservative efficacy (challenge test). Run to ISO 11930:2019 or an equivalent licensed method, on the final formula in the final pack. Evidence: PET report carrying formula version, preservative version, fragrance version and pack version IDs.
  • Packaging compatibility. Dispense dose, actuation force, leak, label adhesion, and fragrance–elastomer interaction at elevated temperature. Evidence: compatibility report plus 45 °C pack photographs at defined intervals.
  • Bulk hold-time validation and retention samples. A protocol-defined hold time under defined tank, temperature and mixing conditions, and finished-goods retention samples stored in a controlled environment under a long-term observation plan. Evidence: hold-time protocol, tank logs, retention register.

The control IDs you must carry across the transfer

Your old data does not belong to “the serum.” It belongs to a version set. When you brief the new factory, these IDs are the transfer language — and any one of them changing on their side reopens the question of whether the old report still represents the product.

Control item Reference to carry over What breaks if it changes Evidence to request from the new factory
Formula Formula version (e.g., F1), full quantitative formula with tolerances Any % or raw-material source shift changes stability and preservative load Signed formula match statement vs. F1, plus raw-material COAs
Preservative system Preservative version (e.g., PRES-V1) and supplier Invalidates the challenge test result Preservative COA and PET re-test or risk-assessment rationale
Fragrance Fragrance version (e.g., FR-V1), supplier, allergen declaration Changes allergen profile, oxidation risk, plastic interaction New IFRA certificate, allergen declaration, label warning review
Primary packaging Pack version (e.g., PKG1): resin, liner, pump/dropper, decoration Leak, dose drift, label lift, discolouration at 45 °C Pack spec, compatibility report, 45 °C pack stability with photos
Process Process version (e.g., P1): temperatures, homogenisation, pH adjustment, fill temperature Changes droplet size, viscosity, emulsion stability Process flowchart with parameters and pilot batch records
Test method ISO 11930:2019 and the stability protocol version New lab using a different method makes results non-comparable Method statement and lab accreditation/qualification evidence
Bulk hold Approved hold time, tank type, open/closed, temperature, mixing Micro and viscosity drift before filling Hold-time validation protocol and deviation procedure

Step-by-step transfer protocol

1. Freeze the outgoing factory’s dossier before you negotiate

Request the complete technical file while you still have commercial leverage. Minimum set: full quantitative formula, specification sheet, raw-material COAs, three consecutive commercial batch records, stability report with protocol version and photographs, PET report, SDS, packaging specification and compatibility notes, complaint/adverse-event summary, and the label artwork with the claims substantiation behind each claim. Anything not in your hands before the last purchase order closes is effectively lost.

2. Run a raw-material equivalence check — same INCI is not the same material

Two suppliers of “the same” botanical extract or active can differ in active content, salts, solvent, particle size, degree of polymerisation, impurities, colour, odour and even the preservative they carry. Require a side-by-side COA comparison, then a lab batch, then key stability checks on pH, viscosity and appearance before any pilot commitment. Treat a botanical or fragrance supplier substitution at the new site as a high-risk change, not a housekeeping detail.

3. Build a side-by-side pilot batch

Ask for a pilot batch made to F1 on P1 in the new plant, tested against the retained old-factory sample: pH, viscosity, colour (instrumental or standardised photo), odour panel, centrifugal and freeze–thaw stability, and micro. Comparability is the argument that lets you keep your history — not identity of the ingredient list.

4. Re-qualify the pack at temperature

If the new factory sources a different dropper, pump, liner or label stock, you have a new pack version. Test dose consistency, actuation force, leak/tip-over, label adhesion and fragrance–plastic interaction after elevated-temperature storage, and record it with photographs at each interval. A serum that passes 45 °C in a glass dropper can fail in an airless pump with a different elastomer.

5. Re-run only what the risk assessment justifies — but document the decision

Not every transfer needs a full re-test programme. It does need a written, signed risk rationale naming what was re-tested, what was bridged by comparability, and why. If preservative, fragrance, pack or process changes, expect the challenge test question to reopen; if the bulk hold changes, expect a hold-time revalidation.

6. Lock label, warnings and claims before the first commercial batch

Allergen declarations follow the fragrance. Claims follow the data. A serum transferred to a new formula version inherits neither automatically. Map every on-pack and listing claim to a substantiation document generated on the new version, and screen product naming for implied claims that regulators and marketplaces read literally.

7. Hand off retention, surveillance and documentation duties in writing

Confirm who holds retention samples, at what conditions, on what timepoint plan, and who owns post-market adverse-event monitoring for Gulf batches. Put it in the quality agreement, not in an email thread.

Red lines: what not to cut to save time

  • Do not ship without a signed formula-version match to F1, including raw-material sources.
  • Do not accept a PET report from a different preservative version, fragrance version or pack version.
  • Do not skip elevated-temperature and thermal-cycling testing because “the formula is identical.”
  • Do not launch on a new pack without compatibility data at Gulf-representative temperatures.
  • Do not release bulk that exceeded its protocol-defined hold time without micro re-test.
  • Do not carry a claim across the transfer without substantiation generated on the new version.
  • Do not accept a certificate of analysis that does not name the batch, the spec version and the test method.

Six failure modes and how to prevent them

1. “Same formula,” different behaviour at month three

  • Symptom: pH drift, colour shift or viscosity loss in the new factory’s accelerated samples that never appeared in the old data.
  • Root cause: a raw-material supplier substitution with identical INCI but different impurity profile, active level or pH.
  • Prevention: COA comparison → lab batch → key stability (pH, viscosity, appearance) before pilot approval.
  • Evidence to request: side-by-side COAs of old vs. new raw materials, lab batch record, comparative test data.

2. Packaging compatibility failure

  • Symptom: serum weeps at the pump collar, dose becomes inconsistent, label edges lift, or the product discolours near the neck after six weeks in a Gulf warehouse.
  • Root cause: a new pack version (different resin, liner, elastomer or adhesive) or a viscosity shift that no longer matches the dispenser’s dose design; fragrance components interacting with plastic.
  • Prevention: hold PKG1 or qualify the new pack with elevated-temperature storage plus leak, dose and adhesion testing.
  • Evidence to request: pack specification and drawings, compatibility report, 45 °C pack photographs at each interval, dose/actuation measurements.

3. Documentation failure at the border or the distributor

  • Symptom: registration or listing is queried; COA, SDS or stability report missing; the INCI on the new label does not match the old certificate.
  • Root cause: the transfer sent a formula, not a dossier; no version control on documents; different INCI declaration conventions between sites.
  • Prevention: a signed transfer-dossier checklist completed before pilot approval, with document version numbers on every file.
  • Evidence to request: three consecutive batch records, per-lot COAs, SDS, stability and PET reports with protocol versions, INCI declaration reconciliation.

4. Preservative efficacy gap at the new site

  • Symptom: rising micro counts in bulk or finished goods; no valid challenge test for the new site’s output.
  • Root cause: different water system, tank sanitation, filling environment or preservative supplier — the old “pass” no longer represents the new product.
  • Prevention: PET on a new-site batch in the final pack, plus a documented risk rationale if bridging instead of re-testing.
  • Evidence to request: PET report naming batch, pack and method version; water and environmental monitoring data.

5. Bulk hold-time overrun

  • Symptom: separation, viscosity drop or an out-of-spec micro result after bulk waits over a weekend.
  • Root cause: hold time defined loosely or exceeded; open vs. closed tank conditions not specified.
  • Prevention: protocol-defined hold with tank, temperature and mixing conditions; mandatory micro re-test if exceeded.
  • Evidence to request: hold-time validation protocol, tank condition logs, deviation procedure.

6. Claims and naming carried over unchecked

  • Symptom: marketplace rejection, retailer challenge or authority query on wording.
  • Root cause: implied claims travel with the artwork even when the substantiation does not.
  • Prevention: claims mapping per SKU, substantiation on the new version, and a naming review that flags implied efficacy language.
  • Evidence to request: claim substantiation file, label artwork approval record, INCI and allergen reconciliation.

Realistic transfer timeline

Durations below are typical planning ranges for a leave-on serum; confirm against your lab’s lead times and your market’s registration queue.

Phase Typical duration Evidence produced
Dossier retrieval and gap review 1–3 weeks Signed transfer checklist, document version register
Raw-material equivalence and lab batch 2–4 weeks COA comparison, lab batch record, comparative pH/viscosity/appearance
Pilot batch and packaging qualification 3–5 weeks Pilot batch record, pack compatibility report, elevated-temperature photos
Stability, thermal cycling and PET start Accelerated: 3–6 months; real-time continues 12–36 months Stability protocol and interim reports, PET report, cycling report
Label, claims and registration file update 2–8 weeks, parallel Approved artwork, claim substantiation file, updated registration dossier
First commercial batch and handoff 2–4 weeks Batch record, COA, retention register, quality agreement

FAQ

Can the new factory simply reuse the old factory’s stability report?

Only where comparability is demonstrated and documented. The report is valid for the formula, preservative, fragrance, pack, process and method versions it was run on. If those match and a written risk rationale supports bridging, you can reference it; if any of them changed, expect to generate new data or justify the gap formally.

The formula is unchanged — do we still need a new challenge test?

Not automatically, but the decision must be documented. A change of manufacturing site alters water quality, tank sanitation and filling conditions, and a change of preservative or fragrance supplier alters the preservative load. Run a risk assessment; if the outcome is “re-test,” test the new site’s batch in the final pack to ISO 11930:2019 or a licensed equivalent.

What if the new factory uses a different fragrance or botanical supplier?

Treat it as a high-risk change. Re-review the ingredient safety profile, reassess consumer exposure, evaluate whether scalp or facial tolerance testing is needed, and update allergen warnings and any registration documentation. Botanical and fragrance changes also commonly reopen the stability and preservative questions, so budget for re-testing rather than assuming a pass.

How long before we can ship Gulf orders?

Plan on three to six months from pilot approval to a defensible launch decision, driven mainly by accelerated stability and any re-testing. Real-time data continues after launch — that is normal, provided you commit to a timepoint plan and hold retention samples in a controlled environment.

Do the Gulf registration documents need updating for a site change?

Usually yes, at minimum the manufacturer details and any supporting safety documentation. Requirements differ between Saudi SFDA, UAE MOHAP and other GCC authorities, and between product categories. Confirm the specific filing impact with your regulatory lead before the first shipment.

Informational only, not legal or regulatory advice. Confirm testing scope and filing requirements with your safety assessor and the relevant market authority.

Ready to scope a transfer? Bring your target market, SKU list and formats, positioning, packaging direction and timeline target to Request a Quote and the feasibility and testing plan can be mapped in one pass.

Hi, I'm your LAEYO representative, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.

  • Our team will answer your inquiries within 8 hours.
  • Your information will be kept strictly confidential.

Request received

Thanks — we’ve received your request. Our team will follow up shortly. we typically reply within 8 hours (often sooner).